The British Novavax trial involved 15,000 people age 18 to 84, including 27 per cent who were over the age of 65. Photo: Reuters
Novavax coronavirus vaccine highly effective, but not against South Africa variant
- The US biotech firm said the product showed 89.3 per cent efficacy in a phase 3 trial in Britain
- Novavax says it will begin developing a new vaccine to target the highly infectious strain first found in South Africa
Topic |
Coronavirus pandemic
The British Novavax trial involved 15,000 people age 18 to 84, including 27 per cent who were over the age of 65. Photo: Reuters